vimarsana.com
Home
Live Updates
Drug Administration Grants Priority Review For Axatilimab - Breaking News
Pages:
Latest Breaking News On - Drug administration grants priority review for axatilimab - Page 1 : vimarsana.com
Incyte Announces U S Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
Incyte today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD).
United states
Drug administration
American society of hematology annual meeting
American association of hematology annual meeting
Product service
Exchange commission
Syndax pharmaceuticals nasdaq
Drug administration grants priority review for axatilimab
Drug administration grants priority review
Chronic graft versus host
Priority review
Biologics license application
Prescription drug user fee act
Plenary scientific session
American society
Hematology annual meeting
vimarsana © 2020. All Rights Reserved.